Neuroalgology Unit, Foundation IRCCS Carlo Besta Neurological Institute, Milan, Italy.
Neurorehabilitation Department, IRCCS Istituti Clinici Scientifici Maugeri di Milano, Milan, Italy.
Cephalalgia. 2022 Aug;42(9):918-925. doi: 10.1177/03331024221088994. Epub 2022 Mar 25.
About 26 million people are living with HIV in sub-Saharan Africa. The DREAM programme in sub-Saharan Africa provides free healthcare for HIV/AIDS and a range of chronic non-communicable diseases. HIV is a risk factor for neurological non-communicable diseases including stroke and epilepsy, which themselves are associated with headache, and HIV may be a direct risk factor for headache. We investigated the prevalence and burden of headache in a HIV+ population in sub-Saharan Africa.
At the DREAM Centre in Blantyre, Malawi, a low-income country with a population of 19 million and 9.2% HIV prevalence, a structured questionnaire was administered by a trained lay interviewer to consecutively attending HIV+ patients aged 6-65 years. All were monitored with regular viral load detection.
Of 513 eligible patients invited, 498 were included (mean age 34.1 ± 12.8 years; 72% females; 15 declined). All were on antiretroviral treatment, with viral load undetectable in 83.9%. The 1-year prevalence of headache was 80.3% (females 83.6%, males 71.9%); 3.8% had ≥15 headache days/month, 1.4% had probable medication-overuse headache. Mean overall headache frequency was 4.4 ± 5.4 days/month. Those reporting headache lost means of 2.3% of paid workdays and 3.3% of household workdays because of headache. Only one third had sought advice for their headache.
Headache is very prevalent among HIV+ patients in Malawi, imposing additional burden and costs on individuals and the community. Management of headache disorders should be implemented in HIV centres, as it is for other chronic non-communicable diseases.
撒哈拉以南非洲地区约有 2600 万人感染艾滋病毒。撒哈拉以南非洲的 DREAM 计划为艾滋病毒/艾滋病和一系列慢性非传染性疾病提供免费医疗保健。艾滋病毒是包括中风和癫痫在内的神经非传染性疾病的一个风险因素,而这些疾病本身与头痛有关,艾滋病毒也可能是头痛的一个直接风险因素。我们研究了撒哈拉以南非洲艾滋病毒阳性人群中头痛的患病率和负担。
在马拉维布兰太尔的 DREAM 中心,我们对年龄在 6-65 岁的连续就诊的艾滋病毒阳性患者进行了一项由经过培训的非专业调查员进行的结构化问卷调查。所有患者均定期进行病毒载量检测。
在邀请的 513 名符合条件的患者中,有 498 名患者(平均年龄 34.1±12.8 岁;72%为女性;15 人拒绝)入选。所有患者均接受抗逆转录病毒治疗,83.9%的患者病毒载量不可检测。头痛的 1 年患病率为 80.3%(女性为 83.6%,男性为 71.9%);3.8%的患者每月头痛天数≥15 天,1.4%的患者患有可能的药物过度使用性头痛。平均每月头痛总频率为 4.4±5.4 天。报告头痛的患者因头痛而损失了 2.3%的有酬工作日和 3.3%的家务工作日。只有三分之一的患者曾就头痛寻求过建议。
头痛在马拉维的艾滋病毒阳性患者中非常普遍,给个人和社区带来了额外的负担和成本。应该像管理其他慢性非传染性疾病一样,在艾滋病毒中心实施头痛疾病的管理。